Xilio Therapeutics, Inc.
XLO
$7.73
$0.000.00%
NASDAQ
Corporate Info
Website
Phone Number
857 524 2466
Address
828 Winter Street
Suite 300
Waltham, MA 02451
Suite 300
Waltham, MA 02451
Country
United States
Year Founded
2016
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
Business Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company’s pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.